Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.

She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on 

Articles

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

FDA Approves Imuldosa, a Fifth Biosimilar to Stelara

Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.

She has a BA in English from Penn State University. You can connect with Maggie on 

Outcomes of interest in this study were time from diagnosis to initial prescription fill for an oral multiple myeloma (MM) medication and time from initial diagnosis to receipt of any treatment for MM.

Delays in Myeloma Oral Therapy Linked to Race, Age

An integrated, rule-based informatics system demonstrated its capacity to leverage electronic health records to streamline the prior authorization process and promote the use of biosimilars. 

Streamlining PA Process, Promoting Biosimilars With Automated Informatics

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

Patients with endocrine-resistant, HER2-negative, locally advanced or metastatic breast cancer can use the treatment after recurrence or completing adjuvant endocrine therapy.

FDA Approves Inavolisib in Locally Advanced, Metastatic Breast Cancer

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiovascular

Chronic Kidney Disease

Diabetes

Heart Failure

Type 1 Diabetes

Cardiorenalmetabolic

Alopecia

Atopic Dermatitis

Psoriasis

Dermatology

ALL/AML

CLL/SLL

GVHD

Hemophilia

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Rare Blood

Hematology

Liver

Hepatology

Autoimmune

Inflammation

Lupus

Myasthenia Gravis

Immunology

COVID-19

Vaccines

Infectious Disease

Major Depressive Disorder

Sleep

Mental Health

Duchenne Muscular Dystrophy

Epilepsy

Multiple Sclerosis

Parkinson Disease

Neurology

Obesity

Breast Cancer

Cholangiocarcinoma

Colorectal Cancer

Immuno-Oncology

Liver Cancer

Lung Cancer

Non–Small Cell Lung Cancer

Ovarian Cancer

Prostate Cancer

Skin Cancer

Soft Tissue Sarcoma

Oncology

Ophthalmology

COPD

Pulmonary Arterial Hypertension

Pulmonology

Spinal Muscular Atrophy

Rare Disease

Asthma

Idiopathic Pulmonary Fibrosis

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Employers

Medicare

Reimbursement

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Impact of a Prior Authorization for Pregabalin on Health Plan Drug Expenditures

eAppendix

Pregabalin: An Alpha2-delta (a2-d) Ligand for the Management of Fibromyalgia

Financial and Clinical Characteristics of Fibromyalgia: A Case-Control Comparison

Initial Use of Pregabalin, Patterns of Pain-Related Pharmacotherapy, and Healthcare Resource Use Among Older Patients With Fibromyalgia

Introduction

Participating Faculty

Patterns of Healthcare Utilization and Cost in Patients With Newly Diagnosed Fibromyalgia